Equities research analysts at William Blair issued their Q1 2025 earnings per share estimates for MiNK Therapeutics in a ...

Q4 2024 Earnings Call Transcript March 18, 2025 MiNK Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

MiNK Therapeutics Inc (INKT) showcases promising clinical progress and strategic partnerships while navigating financial hurdles and leadership changes.

We ended the year with a cash balance of $4.6 million. Cash used in operations for the three and twelve months ended December 31, 2024, was $1.7 million, and $9.6 million, respectively, compared to $3 ...

MiNK advanced its mission to bring off-the-shelf iNKT cell therapies to patients fighting hard-to-treat cancers and severe ...

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in invariant natural killer T (iNKT) cell therapies, announced its financial results for the fourth quarter and ...

MiNK Therapeutics shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. Dylan Berman Why Byrna Technologies ...

“These latest data demonstrate the remarkable potential of combining BOT/BAL with a novel iNKT cell therapy to broaden and intensify immune responses against resistant gastric tumors,” said Dr ...

MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) – Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of MiNK Therapeutics in a report ...